Bausch Health CompaniesNYSE: BHC

LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m.

LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Norwich Pharmaceuticals, Inc. This lawsuit was filed in connection with the Notice of Paragraph IV Certification, dated May 10, 2024, received from Norwich advising that it has submitted to the U.S. Food and Drug Administration (FDA) an amendment to an Abbreviated New Drug Application (ANDA) requesting approval to market a generic version of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Bausch Health continues to defend challenges to its XIFAXAN® intellectual property.

LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, recently presented at two global healthcare conferences. Bausch Health's gastroenterology (GI) business, Salix Pharmaceuticals presented data from its Amiselimod clinical trials at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on May 19, 2024, in Washington, D.C.

Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments, including Vision Care, Surgical, and Pharmaceuticals. Bausch + Lomb's CEO, the veteran Pharma dealmaker Brent Saunders, has praised the performance of the existing business and hinted at a focus on existing products and targeting growth.

Bausch Health Companies Inc. and Salix Pharmaceuticals will share results from their Phase 2 trial of Amiselimod for active ulcerative colitis at Digestive Disease Week (DDW) 2024 in Washington, D.C. on May 19, 2024.

Bausch (BHC) reports first-quarter earnings and sales below expectations, causing its shares to drop in reaction to the news.

Bausch Health reported quarterly earnings of $0.59 per share, which fell short of the Zacks Consensus Estimate of $0.75 per share. This is higher than the $0.52 per share earnings reported in the same quarter last year.

Bausch Health Companies [BHC] Q1 2024 Earnings Conference Call on May 2, 2024 at 8:00 AM ET featuring CEO Thomas Appio, Interim CFO John Barresi, and IR Garen Sarafian, with participants from Jefferies, TD Cowen, RBC Capital Markets, Evercore ISI, Bank of America, Piper Sandler, Truist Securities. Operator: Welcome to the Bausch Health first quarter 2024 earnings call.

Bausch (BHC) could see an increase in value due to increasing confidence in its earnings potential, as evidenced by its upgrade to a Zacks Rank #2 (Buy).